Business Description
Abera Bioscience AB
ISIN : SE0015245097
Share Class Description:
FRA:8WK: Ordinary SharesTotal Employee Number:
6Compare
Compare
Traded in other countries / regions
ABERA.Sweden8WK.Germany IPO Date
2021-05-04Description
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.8 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 28.1 | |||||
3-Year EPS without NRI Growth Rate | 27.6 | |||||
3-Year FCF Growth Rate | 49.1 | |||||
3-Year Book Growth Rate | -7.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.82 | |||||
9-Day RSI | 27.85 | |||||
14-Day RSI | 37.3 | |||||
3-1 Month Momentum % | 18.48 | |||||
6-1 Month Momentum % | 36.76 | |||||
12-1 Month Momentum % | 4.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.27 | |||||
Quick Ratio | 4.27 | |||||
Cash Ratio | 3.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13 | |||||
Shareholder Yield % | -5.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -108.69 | |||||
ROA % | -80.67 | |||||
ROIC % | -269.31 | |||||
3-Year ROIIC % | 111.61 | |||||
ROC (Joel Greenblatt) % | -1730.86 | |||||
ROCE % | -108.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.31 | |||||
Price-to-Tangible-Book | 9.77 | |||||
EV-to-EBIT | -7.48 | |||||
EV-to-EBITDA | -7.56 | |||||
EV-to-FCF | -7.34 | |||||
| Price-to-Net-Current-Asset-Value | 11.4 | |||||
| Price-to-Net-Cash | 13.68 | |||||
Earnings Yield (Greenblatt) % | -13.37 | |||||
FCF Yield % | -12.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abera Bioscience AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.1 | ||
| Beta | 0.9027 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 1.92 | ||
| Volatility % | 48.25 | ||
| 14-Day RSI | 37.3 | ||
| 14-Day ATR (€) | 0.021185 | ||
| 20-Day SMA (€) | 0.7394 | ||
| 12-1 Month Momentum % | 4.82 | ||
| 52-Week Range (€) | 0.444 - 0.838 | ||
| Shares Outstanding (Mil) | 21.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abera Bioscience AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abera Bioscience AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-15 | In 168 days | ||
| Third quarter earnings results for 2026 | 2026-11-17 | In 78 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 0.71 (+0.00%) | ||
| General meeting for 2025 | 2026-06-10 13:00 | 0.63 (+1.61%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.56 (+1.08%) | ||
| Annual report for 2025 | 2026-05-11 | 0.56 (-1.05%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 0.54 (+0.94%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.47 (-4.86%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 0.64 (+0.00%) | ||
| General meeting for 2024 | 2025-06-11 13:00 | 0.67 (+0.75%) |
Show
Entries
Abera Bioscience AB Frequently Asked Questions
What is Abera Bioscience AB(FRA:8WK)'s stock price today?
The current price of FRA:8WK is €0.68. The 52 week high of FRA:8WK is €0.84 and 52 week low is €0.44.
When is next earnings date of Abera Bioscience AB(FRA:8WK)?
The next earnings date of Abera Bioscience AB(FRA:8WK) is 2026-11-17.
Does Abera Bioscience AB(FRA:8WK) pay dividends? If so, how much?
Abera Bioscience AB(FRA:8WK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Abera Bioscience AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers